IMMUNE RESPONSE OF HCV INFECTION

这是一个协作多阶段项目的持续努力，以 研究人类和实验动物的免疫反应。 在他们感染了人类丙型肝炎病毒后。在最初的阶段， 商业检测试剂盒用于检测丙型肝炎病毒蛋白的抗体 在已知的非甲非乙型肝炎患者血清中。这提供了 丙型肝炎病毒感染及其感染的血清学资料 与其他临床测定的关系。第二阶段 研究将集中在免疫优势表位的鉴定上 和中和表位。这一阶段的研究范围是 范围广泛，耗时长。该项目的第三阶段将 包括利用免疫反应的知识来开发预防性的 对这种病毒感染的致病性的策略和理解。 在确定可能的关系时，将特别注意 丙型肝炎病毒感染者的免疫反应与高度慢性化之间的关系 病人。这项研究的一个部分是转移技术和程序 在实验室研究中发展到我们的临床研究。我们有 开发了一种增殖试验来测量小鼠对 重组丙型肝炎病毒核心蛋白。然后，我们采用了在 与小鼠合作开发区分慢性感染的程序 康复患者中的患者。在95财年和96财年，我们发起了 一项研究丙型肝炎病毒核酸疫苗潜力的新项目。 在这种核子中发展出来的知识、技术和材料 酸性疫苗研究也将补充我们在以下方面的持续努力 了解丙型肝炎病毒感染的免疫反应。的长期目标是 这两个项目都将导致慢性阻塞性肺病免疫治疗模式的发展。 肝脏的病毒感染。

This is a continuous effort of a collaborative multi-phase project to investigate the immune response in both humans and experimental animals after their infection with human hepatitis C virus. In the initial phase, the commercial testing kits were used to detect antibodies to HCV proteins in the known non-A, non-B hepatitis patient sera. This provided information on the serological data of hepatitis C virus infection and its relationship to other clinical determinations. The second phase of the study will concentrate on the identification of immune dominant epitopes and neutralizing epitopes. The scope of this phase of study will be extensive and time-consuming. The third phase of the project will encompass using the knowledge of the immune response to develop preventive strategy and understanding of the pathogenicity of this viral infection. Special attention will be paid in identifying the possible relationship between the immune response and the high chronicity in HCV infected patients. One part of this study is to transfer techniques and procedures developed in the laboratory studies to our clinical studies. We have developed a proliferation assay to measure the immune response in mice to recombinant HCV core proteins. We then adopted the experience learned in working with mice to develop procedures to differentiate chronic infected patients from the recovered ones. During FY '95 and FY '96, we initiated a new project to examine the potential for a nucleic acid vaccine for HCV. The knowledge, the techniques and the material developed in this nucleic acid vaccine study will also complement our continued effort in understanding the immune response in HCV infection. The long-term goal of both projects will lead to developing models of immune therapy of chronic viral infection of the liver.